|
Health
|
Semaglutide's Potential in Heart Failure and Beyond
2024-08-23 05:50:08
Health
Medicine
Science

Semaglutide's Potential in Heart Failure and Beyond

Image used under license from Shutterstock.com

Semaglutide, present in Ozempic and Wegovy, shows promise in reducing cardiovascular events and deaths in heart failure patients due to its impact on various factors like blood pressure and inflammation. Additionally, Tirzepatide offers similar health benefits.

GLP-1 drugs are proving effective in managing conditions beyond diabetes, with potential to aid in alcohol use disorder, cancer, and more. While a study raises concerns about suicidal ideation, regulatory bodies have not confirmed the link.

Despite HIMS' growth prospects, legal uncertainties and competition challenge its GLP-1 products. Expansion plans and strong financial standing position HIMS positively, but potential subscriber churn remains a concern amidst evolving obesity treatment options.

The press radar on this topic:

seekingalpha
22. August 2024 um 20:00

Hims & Hers: More GLP-1 Uncertainties Ahead, Despite Robust Growth Prospects

Economy
Finance
HIMS, a healthcare company, has seen a -32% YTD stock price decline despite robust growth prospects. The company's compounded GLP-1 products face legal uncertainties due to FDA warnings and competition from approved drugs like Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro. A Hunterbrook writer reportedly obtained a semaglutide prescription without medical records, raising concerns. HIMS plans to expand its compounded offerings to include tirzepatide and liraglutide. The company has..
futurism
22. August 2024 um 21:03

New Study Establishes Link Between Ozempic and Suicidal Thoughts

A JAMA study found semaglutide in Ozempic/Wegovy linked to 45% higher risk of suicidal ideation vs. other diabetes drugs. Researchers analyzed WHO and FDA data. Novo Nordisk disputes the findings, stating known risks are reflected in product labeling. The US FDA and European Medicines Agency found no clear relationship. STAT News reports the FDA is not commenting on the third-party research.
forbes
22. August 2024 um 22:30

Semaglutide Reduces Risk Of Harmful Cardiovascular Events And Death In People With Heart Failure, New Study Suggests

Semaglutide, the active ingredient in Ozempic and Wegovy, may reduce cardiovascular events and death in people with heart failure. The study found semaglutide lowered major adverse cardiovascular events by 28% and cardiovascular-related deaths by 24%. Semaglutide's benefits may stem from its effects on blood pressure, blood sugar, inflammation, and heart/vessel function. Tirzepatide, branded as Mounjaro and Zepbound, is another GLP-1 drug with potential cardiovascular, metabolic, and other hea..
Yahoo!
22. August 2024 um 22:30

Weight loss drug’s heart benefits extend to people with heart failure – study

Semaglutide, a weight loss drug with brand names Wegovy and Ozempic, prevents heart attacks and strokes in obese/overweight people with heart disease, including those with heart failure like reduced ejection fraction. Lead author Deanfield of UCL Institute of Cardiovascular Science found it reduced major adverse cardiac events by 28% - 12.3% in placebo vs 9.1% in semaglutide group - in 4,286 of 17,605 participants from the Semaglutide and Cardiovascular Outcomes (Select) trial over an average..
CW

Account

Waiting list for the personalized area


Welcome!

InfoBud.ai

infobud.ai is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand

Spotlighting today's most mentioned stocks in the media. Uncover the stories making waves in the stock market:

A closer look at the individuals who are leading today's news narratives. Find out what makes them the center of attention.

Exploring the five locations receiving the most media attention in the last 24 hours. Discover what puts these places in the global spotlight

Your World, Tailored News: Navigate The News Jungle With AI-Powered Precision!

News

All News
Politics
Technology
Economy
Business
Climate

About

About Us
Team + Mission

Legal

Cookie Settings
Disclaimer
Legal Notice
Data Privacy

Contact

Contact